Shanxi Jinbo Bio-Pharmaceutical(920982)
Search documents
北交所上市公司锦波生物大宗交易溢价32.36%,成交金额1633.5万元
Sou Hu Cai Jing· 2026-02-06 12:28
每日经济新闻 每经讯,2026年2月6日,北交所上市公司锦波生物(920982,收盘价:224.39元)发生一笔大宗交易,成交价297元/股,成交数 量5.5万股,成交金额1633.5万元,溢价32.36%。买入营业部是财通证券股份有限公司杭州秋涛路证券营业部,卖出营业部是东 北证券股份有限公司杭州市心北路证券营业部。 免责声明:本文内容与数据仅供参考,不构成投资建议,使用前核实。据此操作,风险自担。 (记者 曾健辉) ...
锦波生物(920982) - 关于使用闲置自有资金购买理财产品的进展公告
2026-02-05 11:00
证券代码:920982 证券简称:锦波生物 公告编号:2026-007 山西锦波生物医药股份有限公司 关于使用闲置自有资金购买理财产品的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个 别及连带法律责任。 一、 授权委托理财情况 (一)审议情况 山西锦波生物医药股份有限公司(以下简称"公司")分别于 2025 年 4 月 19 日、2025 年 5 月 21 日召开第四届董事会第八次会议、2024 年年度股东会, 审议通过了《关于使用暂时闲置自有资金购买理财产品的议案》,在不影响公 司主营业务正常发展,并确保经营需求的前提下,公司拟使用不超过人民币 15 亿元的暂时闲置的自有资金购买安全性高、流动性好、风险低的银行理财产品 (包括但不限于银行定期存单、结构性存款或风险低理财产品等),且该等现 金管理产品不得用于质押,不用于以证券投资为目的的投资行为,相关内容详 见公司在北京证券交易所(www.bse.cn)披露的《使用闲置自有资金购买理财 产品的公告》(公告编号:2025-030)。 (二)披露标准 根据《北京证券 ...
医疗美容板块2月4日涨0.31%,锦波生物领涨,主力资金净流出127.97万元
Zheng Xing Xing Ye Ri Bao· 2026-02-04 08:56
从资金流向上来看,当日医疗美容板块主力资金净流出127.97万元,游资资金净流入2832.91万元,散户 资金净流出2704.94万元。医疗美容板块个股资金流向见下表: 证券之星消息,2月4日医疗美容板块较上一交易日上涨0.31%,锦波生物领涨。当日上证指数报收于 4102.2,上涨0.85%。深证成指报收于14156.27,上涨0.21%。医疗美容板块个股涨跌见下表: | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 920982 | 锦波生物 | 222.64 | 3.55% | 9236.31 | 2.02 Z | | 000615 | *ST美谷 | 3.13 | 0.97% | 8.45万 | 2651.25万 | | 300896 | 爱美客 | 148.32 | 0.51% | 4.21万 | 6.20 Z | | 688363 | 华熙生物 | 48.80 | -0.02% | 5.81万 | 2.82亿 | 以上内容为证券之星据公开信息整理,由AI算法生成(网信算备3101043 ...
医疗美容板块2月3日涨3.9%,爱美客领涨,主力资金净流入7204.82万元
Zheng Xing Xing Ye Ri Bao· 2026-02-03 09:10
证券之星消息,2月3日医疗美容板块较上一交易日上涨3.9%,爱美客领涨。当日上证指数报收于 4067.74,上涨1.29%。深证成指报收于14127.1,上涨2.19%。医疗美容板块个股涨跌见下表: | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 147.57 | 4.56% | 6.51万 | | 9.471Z | | 688363 | 华熙生物 | 48.81 | 3.45% | 9.68万 | | 4.68 Z | | 000615 | *ST美谷 | 3.10 | 0.65% | 7.82万 | | 2406.23万 | | 920982 | 锦波生物 | 215.00 | 0.05% | 7358.95 | | 1.57亿 | 从资金流向上来看,当日医疗美容板块主力资金净流入7204.81万元,游资资金净流出3044.38万元,散户 资金净流出4160.43万元。医疗美容板块个股资金流向见下表: 以上内容为证券之星据公开信息整理,由AI算法 ...
医疗美容板块2月2日涨2.68%,华熙生物领涨,主力资金净流入1亿元
Zheng Xing Xing Ye Ri Bao· 2026-02-02 09:10
| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 688363 | 华熙生物 | 47.18 | 5.24% | 11.82万 | | 5.62 亿 | | 300896 | 爱美客 | 141.14 | 1.01% | 4.75万 | | 6.83 亿 | | 000615 | *ST美谷 | 3.08 | 0.33% | 11.51万 | | 3595.71万 | | 920982 | 锦波生物 | 214.89 | -2.94% | 9949.16 | | 2.17亿 | 从资金流向上来看,当日医疗美容板块主力资金净流入1.0亿元,游资资金净流出4045.64万元,散户资金 净流出5989.44万元。医疗美容板块个股资金流向见下表: 证券之星消息,2月2日医疗美容板块较上一交易日上涨2.68%,华熙生物领涨。当日上证指数报收于 4015.75,下跌2.48%。深证成指报收于13824.35,下跌2.69%。医疗美容板块个股涨跌见下表: | 代码 | 名称 | 主力净流入 (元 ...
医疗美容板块1月29日涨2.96%,爱美客领涨,主力资金净流入1.05亿元
Zheng Xing Xing Ye Ri Bao· 2026-01-29 09:00
证券之星消息,1月29日医疗美容板块较上一交易日上涨2.96%,爱美客领涨。当日上证指数报收于 4157.98,上涨0.16%。深证成指报收于14300.08,下跌0.3%。医疗美容板块个股涨跌见下表: | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300896 | 爱美客 | 144.38 | 4.53% | 5.67万 | 8.03亿 | | 688363 | 华熙生物 | 46.31 | 1.47% | 4.59万 | 2.11亿 | | 920982 | 锦波生物 | 226.88 | 1.35% | 8287.12 | 1.86 Z | | 000615 | *ST美谷 | 3.13 | -1.26% | 10.31万 | 3232.60万 | 从资金流向上来看,当日医疗美容板块主力资金净流入1.05亿元,游资资金净流出7142.76万元,散户资 金净流出3344.19万元。医疗美容板块个股资金流向见下表: | 代码 | 名称 | 主力净流入 (元) | | | | 主力净占比 游资 ...
医疗美容板块1月28日跌1.57%,锦波生物领跌,主力资金净流出4981.38万元
Zheng Xing Xing Ye Ri Bao· 2026-01-28 09:04
从资金流向上来看,当日医疗美容板块主力资金净流出4981.38万元,游资资金净流出538.33万元,散户 资金净流入5519.71万元。医疗美容板块个股资金流向见下表: | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | --- | | 000615 | *ST美谷 | 3.17 | -0.63% | | 6.67万 | | 2120.37万 | | 300896 | 爱美客 | 138.12 | -1.56% | | 2.98万 | | 4.13亿 | | 688363 | 华熙生物 | 45.64 | -1.70% | | 2.88万 | | 1.32亿 | | 920982 | 锦波生物 | 223.85 | -1.97% | | 7323.3 | | 1.65亿 | | 代码 | 名称 | | | 主力净流入(元) 主力净占比 游资净流入(元) 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- ...
医疗美容板块1月27日跌1.41%,*ST美谷领跌,主力资金净流出4131.86万元
Zheng Xing Xing Ye Ri Bao· 2026-01-27 08:57
Market Overview - The medical beauty sector experienced a decline of 1.41% on January 27, with *ST Meigu leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Individual Stock Performance - Aimei Ke (300896) closed at 140.31, down 1.20% with a trading volume of 31,300 shares and a transaction value of 439 million [1] - Jinbo Biological (920982) closed at 228.34, down 1.31% with a trading volume of 5,531 shares and a transaction value of 127 million [1] - Huaxi Biological (688363) closed at 46.43, down 1.59% with a trading volume of 49,700 shares and a transaction value of 229 million [1] - *ST Meigu (000615) closed at 3.19, down 2.15% with a trading volume of 108,900 shares and a transaction value of 34.8 million [1] Capital Flow Analysis - The medical beauty sector saw a net outflow of 41.32 million from main funds and a net outflow of 3.13 million from speculative funds, while retail investors had a net inflow of 44.45 million [1] - For *ST Meigu, the main funds had a net outflow of 9.71 million, accounting for -27.91% of the total, while retail investors had a net inflow of 7.40 million, representing 21.26% [2] - Huaxi Biological experienced a net outflow of 14.32 million from main funds, with a net inflow of 4.64 million from retail investors [2] - Aimei Ke had a net outflow of 17.28 million from main funds, with a net inflow of 32.41 million from retail investors [2] - Jinbo Biological saw a net outflow of 19.33 million from main funds, with a net outflow of 188,440 from retail investors [2]
医疗美容板块1月26日跌0.03%,*ST美谷领跌,主力资金净流出1470.72万元
Zheng Xing Xing Ye Ri Bao· 2026-01-26 09:41
| 代码 | 名称 | | | 主力净流入(元) 主力净占比 游资净流入(元) 游资净占比 散户净流入 (元) 散户净占比 | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 688363 华盛生物 | | 590.51万 | 2.01% | 1656.31万 | 5.63% | -2246.82万 | -7.64% | | 920982 锦波生物 | | -383.62万 | -1.73% | 491.75万 | 2.21% | -75.65万 | -0.34% | | 000615 *ST美谷 | | -746.45万 | -25.02% | 287.49万 | 9.63% | 458.96万 | 15.38% | | 300896 | 爱美客 | -1314.78万 | -2.68% | -1326.43万 | -2.71% | 2641.21万 | 5.39% | | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- ...
未来产业周报第7期(2026、1、18-2026、1、24):双重码降低量子纠错开销,风电直连提升制氢效率-20260125
Shenwan Hongyuan Securities· 2026-01-25 13:42
Group 1: Quantum Technology - The report highlights significant advancements in quantum error correction technology, with Zhejiang University and Tsinghua University demonstrating low-overhead quantum error correction codes, effectively reducing logical error rates below physical error rates [4][5] - Horizon Quantum Computing has formed a strategic partnership with Alice&Bob to accelerate the development of fault-tolerant quantum computing, integrating their software and hardware capabilities [5] - GuoDun Quantum plans to sign a technology licensing contract with the University of Science and Technology of China, involving quantum random number generators and superconducting quantum computing control systems [6][7] Group 2: Biomanufacturing - The Chinese Academy of Sciences has achieved a breakthrough in synthesizing L-arginine using methanol as the sole carbon source, marking a shift towards non-grain-based production methods [8][9] - The Shenzhen Advanced Institute has developed the MARS intelligent system, which integrates multiple AI agents and robots to significantly shorten the new material development cycle from four months to four hours [9][10] - Jinbo Biological has registered a 2 billion yuan private placement to enhance its humanized collagen protein FAST database project, aiming to improve research and development efficiency [11] Group 3: Hydrogen Energy and Nuclear Fusion - The Baowu Clean Energy green hydrogen industrial park project, with a total investment of 11.09 billion yuan, has been launched in Guangdong, establishing a new model for offshore wind power direct hydrogen production [12][13] - A Chinese consortium has signed a significant contract for the ITER edge local model power supply system, marking a major step in China's contribution to global fusion energy projects [15] - Zhejiang Fu Nuclear Power will participate in the development of core components for the China Fusion Engineering Demonstration Reactor (CFEDR), focusing on ultra-high heat load components [16][17] Group 4: Brain-Computer Interfaces - Neuralink has successfully implemented OTA wireless upgrades for its invasive brain-computer interface, allowing for performance optimization without the need for additional surgeries [18][19] - This advancement addresses the traditional limitations of invasive devices, reducing clinical maintenance risks and costs while enhancing the adaptability of the technology [20] Group 5: Embodied Intelligence - World Labs, founded by Fei-Fei Li, has partnered with Guanglun Intelligent to create an evaluation system for embodied intelligence, addressing high verification costs and discrepancies between simulation and reality [21][22] - The Marble model developed by World Labs generates high-fidelity 3D environments from various inputs, solving traditional model issues but lacking physical interaction capabilities [22][23] Group 6: Future Industry Catalysts - The report outlines key catalytic events for 2026 across six future industries, including significant conferences and technological milestones that investors should monitor [28][29]